New insights into Shiga toxin-mediated endothelial dysfunction in hemolytic uremic syndrome

Virulence

Volumn 4, Issue 6, 2013, Pages

  Petruzziello Pellegrini, Tania N ^a,b   Moslemi Naeini, Mozhgan ^a,b   Marsden, Philip A ^a,b,c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Complement; E.coli; Endothelial dysfunction; Endothelium; Hemolytic uremic syndrome; HUS; SDF 1; Shiga toxin; STEC; Verotoxin

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; CIPROFLOXACIN; COMPLEMENT; COMPLEMENT COMPONENT C3A; COMPLEMENT FACTOR H; CREATININE; CYCLOPHILIN A; ECULIZUMAB; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIN 1; GLOBOTRIAOSYLCERAMIDE; INTERCELLULAR ADHESION MOLECULE 1; MESSENGER RNA; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLERIXAFOR; SHIGA TOXIN; STROMAL CELL DERIVED FACTOR 1; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR CELL ADHESION MOLECULE 1; VEROTOXIN 1; VEROTOXIN 2; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ARTICLE; BLOOD VESSEL INJURY; CELL DAMAGE; CLINICAL TRIAL (TOPIC); ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ERYTHROCYTE; ESCHERICHIA COLI INFECTION; ESCHERICHIA COLI O157; FIBRINOLYSIS; FOOD POISONING; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; INTESTINE MUCOSA; NONHUMAN; PHENOTYPE; PROTEIN SYNTHESIS; RNA TRANSLATION; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; THROMBOCYTE ADHESION; TREATMENT OUTCOME; ANIMAL; METABOLISM; MICROBIOLOGY; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; ENDOTHELIUM, VASCULAR; ESCHERICHIA COLI INFECTIONS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; SHIGA TOXIN; SHIGA-TOXIGENIC ESCHERICHIA COLI;

EID: 84882608396     PISSN: 21505594     EISSN: 21505608     Source Type: Journal    
DOI: 10.4161/viru.26143     Document Type: Article

References (85)

1. Johnson S, Waters A. Is complement a culprit in infection-induced forms of haemolytic uraemic syndrome? Immunobiology 2012; 217:235-43; PMID:21852019; http://dx.doi.org/10.1016/j.imbio.2011.07.022
2. Lemaire M, Frémeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, Fakhouri F, Taque S, Nobili F, Martinez F, et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet 2013; 45:531-6; PMID:23542698; http:// dx.doi.org/10.1038/ng.2590
3. Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361:1676-87; PMID:19846853; http://dx.doi.org/10.1056/ NEJMra0902814
4. Karmali MA. Host and pathogen determinants of verocytotoxin-producing Escherichia coli-associated hemolytic uremic syndrome. Kidney Int Suppl 2009; (Suppl):S4-7; PMID:19180132; http://dx.doi. org/10.1038/ki.2008.608
5. Petruzziello TN, Mawji IA, Khan M, Marsden PA. Verotoxin biology: molecular events in vascular endothelial injury. Kidney Int Suppl 2009; (Suppl):S17-9; PMID:19180125; http://dx.doi.org/10.1038/ ki.2008.612
6. Petruzziello-Pellegrini TN, Marsden PA. Shiga toxinassociated hemolytic uremic syndrome: advances in pathogenesis and therapeutics. Curr Opin Nephrol Hypertens 2012; 21:433-40; PMID:22660553; http:// dx.doi.org/10.1097/MNH.0b013e328354a62e
7. Karmali MA, Steele BT, Petric M, Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1983; 1:619-20; PMID:6131302; http://dx.doi.org/10.1016/S0140-6736(83)91795-6
8. Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxinproducing Escherichia coli. J Infect Dis 1985; 151:775-82; PMID:3886804; http://dx.doi.org/10.1093/ infdis/151.5.775
9. Jerse AE, Yu J, Tall BD, Kaper JB. A genetic locus of enteropathogenic Escherichia coli necessary for the production of attaching and effacing lesions on tissue culture cells. Proc Natl Acad Sci U S A 1990; 87:7839-43; PMID:2172966; http://dx.doi.org/10.1073/ pnas.87.20.7839
10. Tarr PI, Gordon CA, Chandler WL. Shiga-toxinproducing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005; 365:1073-86; PMID:15781103
11. Karmali MA, Gannon V, Sargeant JM. Verocytotoxinproducing Escherichia coli (VTEC). Vet Microbiol 2010; 140:360-70; PMID:19410388; http://dx.doi. org/10.1016/j.vetmic.2009.04.011
12. Warshawsky B, Gutmanis I, Henry B, Dow J, Reffle J, Pollett G, Ahmed R, Aldom J, Alves D, Chagla A, et al. Outbreak of Escherichia coli 0157:H7 related to animal contact at a petting zoo. Can J Infect Dis 2002; 13:175-81; PMID:18159389
13. Scheiring J, Andreoli SP, Zimmerhackl LB. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol 2008; 23:1749-60; PMID:18704506; http://dx.doi.org/10.1007/ s00467-008-0935-6
14. Obrig TG. Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease. Toxins (Basel) 2010; 2:2769-94; PMID:21297888; http://dx.doi.org/10.3390/toxins2122769
15. Jansen A, Kielstein JT. The new face of enterohaemorrhagic Escherichia coli infections. Euro Surveill 2011; 16:19898; PMID:21722615
16. Petruzziello-Pellegrini TN, Yuen DA, Page AV, Patel S, Soltyk AM, Matouk CC, Wong DK, Turgeon PJ, Fish JE, Ho JJ, et al. The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice. J Clin Invest 2012; 122:759-76; PMID:22232208; http://dx.doi.org/10.1172/JCI57313
17. Trachtman H, Austin C, Lewinski M, Stahl RA. Renal and neurological involvement in typical Shiga toxinassociated HUS. Nat Rev Nephrol 2012; 8:658-69; PMID:22986362; http://dx.doi.org/10.1038/nrneph. 2012.196
18. Siegler RL. Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome. J Pediatr 1994; 125:511-8; PMID:7931868; http://dx.doi. org/10.1016/S0022-3476(94)70001-X
19. Zoja C, Buelli S, Morigi M. Shiga toxin-associated hemolytic uremic syndrome: pathophysiology of endothelial dysfunction. Pediatr Nephrol 2010; 25:2231-40; PMID:20424866; http://dx.doi.org/10.1007/s00467-010-1522-1
20. Spinale JM, Ruebner RL, Copelovitch L, Kaplan BS. Long-term outcomes of Shiga toxin hemolytic uremic syndrome. Pediatr Nephrol 2013; In press; PMID:23288350; http://dx.doi.org/10.1007/s00467-012-2383-6
21. Rosales A, Hofer J, Zimmerhackl LB, Jungraithmayr TC, Riedl M, Giner T, Strasak A, Orth-Höller D, Würzner R, Karch H; German-Austrian HUS Study Group. Need for long-term follow-up in enterohemorrhagic Escherichia coli-associated hemolytic uremic syndrome due to late-emerging sequelae. Clin Infect Dis 2012; 54:1413-21; PMID:22412065; http:// dx.doi.org/10.1093/cid/cis196
22. Rasko DA, Webster DR, Sahl JW, Bashir A, Boisen N, Scheutz F, Paxinos EE, Sebra R, Chin CS, Iliopoulos D, et al. Origins of the E. coli strain causing an outbreak of hemolytic-uremic syndrome in Germany. N Engl J Med 2011; 365:709-17; PMID:21793740; http:// dx.doi.org/10.1056/NEJMoa1106920
23. Wong CS, Mooney JC, Brandt JR, Staples AO, Jelacic S, Boster DR, Watkins SL, Tarr PI. Risk factors for the hemolytic uremic syndrome in children infected with Escherichia coli O157:H7: a multivariable analysis. Clin Infect Dis 2012; 55:33-41; PMID:22431799; http://dx.doi.org/10.1093/cid/cis299
24. Bielaszewska M, Idelevich EA, Zhang W, Bauwens A, Schaumburg F, Mellmann A, Peters G, Karch H. Effects of antibiotics on Shiga toxin 2 production and bacteriophage induction by epidemic Escherichia coli O104:H4 strain. Antimicrob Agents Chemother 2012; 56:3277-82; PMID:22391549; http://dx.doi. org/10.1128/AAC.06315-11
25. Tarr PI, Karpman D. Editorial commentary: Escherichia coli O104:H4 and hemolytic uremic syndrome: the analysis begins. Clin Infect Dis 2012; 55:760-3; PMID:22670035; http://dx.doi.org/10.1093/cid/ cis533
26. Colic E, Dieperink H, Titlestad K, Tepel M. Management of an acute outbreak of diarrhoeaassociated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study. Lancet 2011; 378:1089-93; PMID:21871657; http://dx.doi.org/10.1016/S0140-6736(11)61145-8
27. Ake JA, Jelacic S, Ciol MA, Watkins SL, Murray KF, Christie DL, Klein EJ, Tarr PI. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics 2005; 115:e673-80; PMID:15930195; http://dx.doi. org/10.1542/peds.2004-2236
28. Ullrich S, Bremer P, Neumann-Grutzeck C, Otto H, Rüther C, von Seydewitz CU, Meyer GP, Ahmadi-Simab K, Röther J, Hogan B, et al. Symptoms and clinical course of EHEC O104 infection in hospitalized patients: a prospective single center study. PLoS One 2013; 8:e55278; PMID:23460784; http://dx.doi. org/10.1371/journal.pone.0055278
29. Johannes L, Römer W. Shiga toxins--from cell biology to biomedical applications. Nat Rev Microbiol 2010; 8:105-16; PMID:20023663
30. Frank C, Werber D, Cramer JP, Askar M, Faber M, an der Heiden M, Bernard H, Fruth A, Prager R, Spode A, et al.; HUS Investigation Team. Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany. N Engl J Med 2011; 365:1771-80; PMID:21696328; http://dx.doi.org/10.1056/ NEJMoa1106483
31. Buchholz U, Bernard H, Werber D, Böhmer MM, Remschmidt C, Wilking H, Deleré Y, an der Heiden M, Adlhoch C, Dreesman J, et al. German outbreak of Escherichia coli O104:H4 associated with sprouts. N Engl J Med 2011; 365:1763-70; PMID:22029753; http://dx.doi.org/10.1056/NEJMoa1106482
32. Croxen MA, Finlay BB. Molecular mechanisms of Escherichia coli pathogenicity. Nat Rev Microbiol 2010; 8:26-38; PMID:19966814
33. Scheutz F, Nielsen EM, Frimodt-Møller J, Boisen N, Morabito S, Tozzoli R, Nataro JP, Caprioli A. Characteristics of the enteroaggregative Shiga toxin/ verotoxin-producing Escherichia coli O104:H4 strain causing the outbreak of haemolytic uraemic syndrome in Germany, May to June 2011. Euro Surveill 2011; 16:19889; PMID:21699770
34. European Centre for Disease Prevention and Control and European Food Safety Authority. Shiga toxin/ verotoxin-producing Escherichia coli in humans, food and animals in the EU/EEA, with special reference to the German outbreak strain STEC O104. Stockholm: ECDC, 2011.
35. Bielaszewska M, Mellmann A, Zhang W, Köck R, Fruth A, Bauwens A, Peters G, Karch H. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. Lancet Infect Dis 2011; 11:671-6; PMID:21703928
36. Mellmann A, Harmsen D, Cummings CA, Zentz EB, Leopold SR, Rico A, Prior K, Szczepanowski R, Ji Y, Zhang W, et al. Prospective genomic characterization of the German enterohemorrhagic Escherichia coli O104:H4 outbreak by rapid next generation sequencing technology. PLoS One 2011; 6:e22751; PMID:21799941; http://dx.doi.org/10.1371/journal. pone.0022751
37. Rohde H, Qin J, Cui Y, Li D, Loman NJ, Hentschke M, Chen W, Pu F, Peng Y, Li J, et al.; E. coli O104:H4 Genome Analysis Crowd-Sourcing Consortium. Opensource genomic analysis of Shiga-toxin-producing E. coli O104:H4. N Engl J Med 2011; 365:718-24; PMID:21793736; http://dx.doi.org/10.1056/ NEJMoa1107643
38. Grad YH, Godfrey P, Cerquiera GC, Mariani-Kurkdjian P, Gouali M, Bingen E, Shea TP, Haas BJ, Griggs A, Young S, et al. Comparative genomics of recent Shiga toxin-producing Escherichia coli O104:H4: short-term evolution of an emerging pathogen. MBio 2013; 4:e00452-12; PMID:23341549; http://dx.doi.org/10.1128/mBio.00452-12
39. Scheutz F, Teel LD, Beutin L, Piérard D, Buvens G, Karch H, Mellmann A, Caprioli A, Tozzoli R, Morabito S, et al. Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature. J Clin Microbiol 2012; 50:2951-63; PMID:22760050; http://dx.doi.org/10.1128/ JCM.00860-12
40. Scotland SM, Smith HR, Willshaw GA, Rowe B. Vero cytotoxin production in strain of Escherichia coli is determined by genes carried on bacteriophage. Lancet 1983; 2:216; PMID:6135046; http://dx.doi. org/10.1016/S0140-6736(83)90192-7
41. O'Brien AD, Newland JW, Miller SF, Holmes RK, Smith HW, Formal SB. Shiga-like toxin-converting phages from Escherichia coli strains that cause hemorrhagic colitis or infantile diarrhea. Science 1984; 226:694-6; PMID:6387911; http://dx.doi. org/10.1126/science.6387911
42. Newland JW, Strockbine NA, Miller SF, O'Brien AD, Holmes RK. Cloning of Shiga-like toxin structural genes from a toxin converting phage of Escherichia coli. Science 1985; 230:179-81; PMID:2994228; http:// dx.doi.org/10.1126/science.2994228
43. Bitzan MM, Wang Y, Lin J, Marsden PA. Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium. J Clin Invest 1998; 101:372-82; PMID:9435309; http://dx.doi.org/10.1172/JCI522
44. Lingwood CA, Binnington B, Manis A, Branch DR. Globotriaosyl ceramide receptor function-where membrane structure and pathology intersect. FEBS Lett 2010; 584:1879-86; PMID:19948172; http:// dx.doi.org/10.1016/j.febslet.2009.11.089
45. Obrig TG, Louise CB, Lingwood CA, Boyd B, Barley-Maloney L, Daniel TO. Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem 1993; 268:15484-8; PMID:8340376
46. Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, Igarashi K. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem 1988; 171:45-50; PMID:3276522; http://dx.doi.org/10.1111/j.1432-1033.1988. tb13756.x
47. Saxena SK, O'Brien AD, Ackerman EJ. Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28 S RNA when microinjected into Xenopus oocytes. J Biol Chem 1989; 264:596-601; PMID:2642481
48. Furutani M, Kashiwagi K, Ito K, Endo Y, Igarashi K. Comparison of the modes of action of a Vero toxin (a Shiga-like toxin) from Escherichia coli, of ricin, and of alpha-sarcin. Arch Biochem Biophys 1992; 293:140-6; PMID:1731630; http://dx.doi.org/10.1016/0003-9861(92)90376-8
49. Obrig TG, Moran TP, Brown JE. The mode of action of Shiga toxin on peptide elongation of eukaryotic protein synthesis. Biochem J 1987; 244:287-94; PMID:3663122
50. Karpman D, Håkansson A, Perez MT, Isaksson C, Carlemalm E, Caprioli A, Svanborg C. Apoptosis of renal cortical cells in the hemolytic-uremic syndrome: in vivo and in vitro studies. Infect Immun 1998; 66:636-44; PMID:9453620
51. Jones NL, Islur A, Haq R, Mascarenhas M, Karmali MA, Perdue MH, Zanke BW, Sherman PM. Escherichia coli Shiga toxins induce apoptosis in epithelial cells that is regulated by the Bcl-2 family. Am J Physiol Gastrointest Liver Physiol 2000; 278:G811-9; PMID:10801274
52. Suzuki A, Doi H, Matsuzawa F, Aikawa S, Takiguchi K, Kawano H, Hayashida M, Ohno S. Bcl-2 antiapoptotic protein mediates verotoxin II-induced cell death: possible association between bcl-2 and tissue failure by E. coli O157:H7. Genes Dev 2000; 14:1734-40; PMID:10898788
53. Tesh VL. The induction of apoptosis by Shiga toxins and ricin. Curr Top Microbiol Immunol 2012; 357:137-78; PMID:22130961; http://dx.doi. org/10.1007/82_2011_155
54. Aird WC. Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ Res 2007; 100:158-73; PMID:17272818; http://dx.doi. org/10.1161/01.RES.0000255691.76142.4a
55. Aird WC. Endothelium in health and disease. Pharmacol Rep 2008; 60:139-43; PMID:18276995
56. Matussek A, Lauber J, Bergau A, Hansen W, Rohde M, Dittmar KE, Gunzer M, Mengel M, Gatzlaff P, Hartmann M, et al. Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells. Blood 2003; 102:1323-32; PMID:12702508; http://dx.doi.org/10.1182/blood-2002-10-3301
57. Louise CB, Obrig TG. Human renal microvascular endothelial cells as a potential target in the development of the hemolytic uremic syndrome as related to fibrinolysis factor expression, in vitro. Microvasc Res 1994; 47:377-87; PMID:8084301; http://dx.doi. org/10.1006/mvre.1994.1030
58. Nestoridi E, Tsukurov O, Kushak RI, Ingelfinger JR, Grabowski EF. Shiga toxin enhances functional tissue factor on human glomerular endothelial cells: implications for the pathophysiology of hemolytic uremic syndrome. J Thromb Haemost 2005; 3:752-62; PMID:15842359; http://dx.doi.org/10.1111/j.1538-7836.2005.01205.x
59. Tashiro K, Tada H, Heilker R, Shirozu M, Nakano T, Honjo T. Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science 1993; 261:600-3; PMID:8342023; http:// dx.doi.org/10.1126/science.8342023
60. Shirozu M, Nakano T, Inazawa J, Tashiro K, Tada H, Shinohara T, Honjo T. Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. Genomics 1995; 28:495-500; PMID:7490086; http://dx.doi.org/10.1006/ geno.1995.1180
61. Takabatake Y, Sugiyama T, Kohara H, Matsusaka T, Kurihara H, Koni PA, Nagasawa Y, Hamano T, Matsui I, Kawada N, et al. The CXCL12 (SDF-1)/CXCR4 axis is essential for the development of renal vasculature. J Am Soc Nephrol 2009; 20:1714-23; PMID:19443644; http://dx.doi.org/10.1681/ASN.2008060640
62. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, Kitamura Y, Matsushima K, Yoshida N, Nishikawa S, et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998; 393:591-4; PMID:9634237; http:// dx.doi.org/10.1038/31261
63. Lévesque JP, Hendy J, Takamatsu Y, Simmons PJ, Bendall LJ. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Invest 2003; 111:187-96; PMID:12531874
64. Panicot-Dubois L, Thomas GM, Furie BC, Furie B, Lombardo D, Dubois C. Bile salt-dependent lipase interacts with platelet CXCR4 and modulates thrombus formation in mice and humans. J Clin Invest 2007; 117:3708-19; PMID:18037996; http://dx.doi. org/10.1172/JCI32655
65. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, Capla JM, Galiano RD, Levine JP, Gurtner GC. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10:858-64; PMID:15235597; http://dx.doi.org/10.1038/nm1075
66. Jin DK, Shido K, Kopp HG, Petit I, Shmelkov SV, Young LM, Hooper AT, Amano H, Avecilla ST, Heissig B, et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 2006; 12:557-67; PMID:16648859; http://dx.doi.org/10.1038/nm1400
67. Strasser GA, Kaminker JS, Tessier-Lavigne M. Microarray analysis of retinal endothelial tip cells identifies CXCR4 as a mediator of tip cell morphology and branching. Blood 2010; 115:5102-10; PMID:20154215; http://dx.doi.org/10.1182/blood-2009-07-230284
68. Ruiz de Almodovar C, Luttun A, Carmeliet P. An SDF-1 trap for myeloid cells stimulates angiogenesis. Cell 2006; 124:18-21; PMID:16413476; http:// dx.doi.org/10.1016/j.cell.2005.12.023
69. Gear AR, Suttitanamongkol S, Viisoreanu D, Polanowska-Grabowska RK, Raha S, Camerini D. Adenosine diphosphate strongly potentiates the ability of the chemokines MDC, TARC, and SDF-1 to stimulate platelet function. Blood 2001; 97:937-45; PMID:11159520; http://dx.doi.org/10.1182/blood. V97.4.937
70. Chandler WL, Jelacic S, Boster DR, Ciol MA, Williams GD, Watkins SL, Igarashi T, Tarr PI. Prothrombotic coagulation abnormalities preceding the hemolyticuremic syndrome. N Engl J Med 2002; 346:23-32; PMID:11777999; http://dx.doi.org/10.1056/ NEJMoa011033
71. Nolasco LH, Turner NA, Bernardo A, Tao Z, Cleary TG, Dong JF, Moake JL. Hemolytic uremic syndromeassociated Shiga toxins promote endothelial-cell secretion and impair ADAMTS13 cleavage of unusually large von Willebrand factor multimers. Blood 2005; 106:4199-209; PMID:16131569; http://dx.doi. org/10.1182/blood-2005-05-2111
72. Morigi M, Zoja C, Figliuzzi M, Foppolo M, Micheletti G, Bontempelli M, Saronni M, Remuzzi G, Remuzzi A. Fluid shear stress modulates surface expression of adhesion molecules by endothelial cells. Blood 1995; 85:1696-703; PMID:7535583
73. Morigi M, Galbusera M, Binda E, Imberti B, Gastoldi S, Remuzzi A, Zoja C, Remuzzi G. Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood 2001; 98:1828-35; PMID:11535517; http://dx.doi.org/10.1182/blood.V98.6.1828
74. Zoja C, Angioletti S, Donadelli R, Zanchi C, Tomasoni S, Binda E, Imberti B, te Loo M, Monnens L, Remuzzi G, et al. Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-kappaB dependent up-regulation of IL-8 and MCP-1. Kidney Int 2002; 62:846-56; PMID:12164866; http://dx.doi. org/10.1046/j.1523-1755.2002.00503.x
75. Kaye SA, Louise CB, Boyd B, Lingwood CA, Obrig TG. Shiga toxin-associated hemolytic uremic syndrome: interleukin-1 beta enhancement of Shiga toxin cytotoxicity toward human vascular endothelial cells in vitro. Infect Immun 1993; 61:3886-91; PMID:8359910
76. Benz K, Amann K. Thrombotic microangiopathy: new insights. Curr Opin Nephrol Hypertens 2010; 19:242-7; PMID:20186056; http://dx.doi.org/10.1097/ MNH.0b013e3283378f25
77. Orth D, Khan AB, Naim A, Grif K, Brockmeyer J, Karch H, Joannidis M, Clark SJ, Day AJ, Fidanzi S, et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 2009; 182:6394-400; PMID:19414792; http://dx.doi.org/10.4049/ jimmunol.0900151
78. Thurman JM, Marians R, Emlen W, Wood S, Smith C, Akana H, Holers VM, Lesser M, Kline M, Hoffman C, et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4:1920-4; PMID:19820137; http://dx.doi.org/10.2215/ CJN.02730409
79. Ståhl AL, Sartz L, Karpman D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 2011; 117:5503-13; PMID:21447825; http://dx.doi.org/10.1182/blood-2010-09-309161
80. Morigi M, Galbusera M, Gastoldi S, Locatelli M, Buelli S, Pezzotta A, Pagani C, Noris M, Gobbi M, Stravalaci M, et al. Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis. J Immunol 2011; 187:172-80; PMID:21642543; http://dx.doi. org/10.4049/jimmunol.1100491
81. Lapeyraque AL, Malina M, Fremeaux-Bacchi V, Boppel T, Kirschfink M, Oualha M, Proulx F, Clermont MJ, Le Deist F, Niaudet P, et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011; 364:2561-3; PMID:21612462; http://dx.doi. org/10.1056/NEJMc1100859
82. Noris M, Mescia F, Remuzzi G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat Rev Nephrol 2012; 8:622-33; PMID:22986360; http://dx.doi.org/10.1038/nrneph.2012.195
83. Menne J, Nitschke M, Stingele R, Abu-Tair M, Beneke J, Bramstedt J, Bremer JP, Brunkhorst R, Busch V, Dengler R, et al.; EHEC-HUS consortium. Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ 2012; 345:e4565; PMID:22815429; http://dx.doi.org/10.1136/bmj. e4565
84. Kielstein JT, Beutel G, Fleig S, Steinhoff J, Meyer TN, Hafer C, Kuhlmann U, Bramstedt J, Panzer U, Vischedyk M, et al. Collaborators of the DGfN STECHUS registry. Best supportive care and therapeutic plasma exchange with or without eculizumab in Shigatoxin-producing E. coli O104:H4 induced haemolyticuraemic syndrome: an analysis of the German STECHUS registry. Nephrol Dial Transplant 2012; 27:3807-15; PMID:23114903; http://dx.doi.org/10.1093/ndt/ gfs394
85. Page AVTP, Tarr PI, Watkins SL, Rajwans N, Petruzziello-Pellegrini TN, Marsden PA, Kain KC, Liles WC. Dysregulation of Angiopoietin 1 and 2 in Escherichia coli O157:H7 Infection and the Hemolytic-Uremic Syndrome. J Infect Dis 2013; In press; PMID:23801605; http://dx.doi.org/10.1093/ infdis/jit268.